This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cha YM et al. (2004) Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109: 2839–2843
Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415: 219–226
Klein HU and Goette A (2003) Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 41: 2205–2206
Allessie MA et al. (2001) Pathophysiology and prevention of atrial fibrillation. Circulation 103: 769–777
Madrid AH et al. (2004) The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27: 1405–1410
McMurray J et al. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45: 525–530
Acknowledgements
The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Deswal, A., Mann, D. Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. Nat Rev Cardiol 2, 502–503 (2005). https://doi.org/10.1038/ncpcardio0325
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0325